BJ Bioscience, Inc., a China-based biotech company, announced on Monday that it has signed a clinical trial collaboration and supply agreement with United States-based Merck & Co., Inc (MSD).
The partnership is intended to enable an assessment of the safety and efficacy of BJ-001, a tumour-targeting IL-15 fusion protein, in combination with MSD's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in an ongoing Phase one clinical trial.
BJ Bioscience is to assess the combination of BJ-001 and KEYTRUDA as part of the company's ongoing trial in subjects with locally advanced/metastatic solid tumours. During this trial, the product is to be studied as monotherapy or in combination with KEYTRUDA, for safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. BJ-001 has showcased tolerable safety profiles, favourable PK/PD profiles, and encouraging preliminary efficacy outcome in monotherapy dose escalation cohorts.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study